FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised) Zacks Equity Research - Zacks Investment Research - Mon Apr 23, 10:19AM CDT Zacks Equity Research - ZACKS - Mon Apr 23, 10:19AM CDT
Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR Zacks Equity Research - Zacks Investment Research - Fri Apr 20, 9:43AM CDT Zacks Equity Research - ZACKS - Fri Apr 20, 9:43AM CDT
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC Zacks Equity Research - Zacks Investment Research - Thu Apr 19, 10:49AM CDT Zacks Equity Research - ZACKS - Thu Apr 19, 10:49AM CDT
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
Model N Founder & CEO Zack Rinat Named Ernst & Young 2018 Entrepreneur of the Year Semifinalist BusinessWire - Thu Apr 19, 8:00AM CDT CMTX - Thu Apr 19, 8:00AM CDT
Model N, Inc. (NYSE: MODN), the leading provider of revenue management
solutions for the pharmaceutical, medical device, high tech,
manufacturing and semiconductor industries, announced that...
Merck's Keytruda Reduces Death Risk in Melanoma Patients Zacks Equity Research - Zacks Investment Research - Mon Apr 16, 8:13AM CDT Zacks Equity Research - ZACKS - Mon Apr 16, 8:13AM CDT
Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer GlobeNewswire - Mon Apr 16, 5:00AM CDT CMTX - Mon Apr 16, 5:00AM CDT
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that it has initiated a Phase 1b/2 clinical trial assessing G1T38, its oral CDK4/6 inhibitor, in combination with...
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data Zacks Equity Research - Zacks Investment Research - Wed Apr 11, 8:36AM CDT Zacks Equity Research - ZACKS - Wed Apr 11, 8:36AM CDT
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca Zacks Equity Research - Zacks Investment Research - Tue Apr 10, 3:14PM CDT Zacks Equity Research - ZACKS - Tue Apr 10, 3:14PM CDT
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Top Analyst Reports for Microsoft, Merck & Union Pacific Mark Vickery - Zacks Investment Research - Mon Apr 9, 3:39PM CDT Mark Vickery - ZACKS - Mon Apr 9, 3:39PM CDT
Top Analyst Reports for Microsoft, Merck & Union Pacific
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy Zacks Equity Research - Zacks Investment Research - Mon Apr 9, 8:54AM CDT Zacks Equity Research - ZACKS - Mon Apr 9, 8:54AM CDT
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status....
Ionis and AstraZeneca Advance New Drug for NASH PR Newswire - Mon Apr 9, 6:00AM CDT CMTX - Mon Apr 9, 6:00AM CDT
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of...
Ionis and AstraZeneca Advance New Drug for NASH PR Newswire - Mon Apr 9, 6:00AM CDT PRNW - Mon Apr 9, 6:00AM CDT
CARLSBAD, Calif. , April 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-L Rx , or...
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus Zacks Equity Research - Zacks Investment Research - Fri Apr 6, 9:11AM CDT Zacks Equity Research - ZACKS - Fri Apr 6, 9:11AM CDT
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review Zacks Equity Research - Zacks Investment Research - Thu Apr 5, 10:34AM CDT Zacks Equity Research - ZACKS - Thu Apr 5, 10:34AM CDT
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
3 Emerging Technologies Set to Transform the Pharma World Kinjel Shah - Zacks Investment Research - Thu Apr 5, 8:08AM CDT Kinjel Shah - ZACKS - Thu Apr 5, 8:08AM CDT
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.
Allergan's Vraylar Meets Endpoints in Bipolar I Phase III Zacks Equity Research - Zacks Investment Research - Wed Apr 4, 10:05AM CDT Zacks Equity Research - ZACKS - Wed Apr 4, 10:05AM CDT
Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use Zacks Equity Research - Zacks Investment Research - Wed Apr 4, 9:08AM CDT Zacks Equity Research - ZACKS - Wed Apr 4, 9:08AM CDT
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States...
Aeglea Initiates Lung Cancer Combination Study With Keytruda Zacks Equity Research - Zacks Investment Research - Tue Apr 3, 7:53AM CDT Zacks Equity Research - ZACKS - Tue Apr 3, 7:53AM CDT
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control BusinessWire - Tue Apr 3, 7:00AM CDT CMTX - Tue Apr 3, 7:00AM CDT
AstraZeneca today announced the US Food and Drug Administration (FDA)
has approved BYDUREON(R) (exenatide extended-release) for
injectable suspension as an add-on therapy to basal insulin...
US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia BusinessWire - Tue Apr 3, 6:00AM CDT CMTX - Tue Apr 3, 6:00AM CDT
AstraZeneca and MedImmune, its global biologics research and development
arm, today announced that the US Food and Drug Administration (FDA) has
accepted the Biologics License Application...
